Clinical trial

Immunotherapy in Patient With Poor General Condition

NCT04108026

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-10-14

PhasePHASE2

Study timeline

Study start (actual)2020-10-14Date precision: day

Registry last updated2025-10-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer Stage IVunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Sponsors & collaborators

Intergroupe Francophone de Cancerologie Thoraciquelead sponsor

Mapped research locations

ParisFrance3 ToulouseFrance1 MarseilleFrance1 MontpellierFrance1 StrasbourgFrance1 LilleFrance1 NantesFrance1 CaenFrance1 GrenobleFrance1 BesançonFrance1 ToursFrance1 Pierre-BéniteFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04108026 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.